Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
3.370
-0.130 (-3.71%)
At close: Sep 18, 2026, 4:00 PM EDT
3.420
+0.050 (1.48%)
After-hours: Sep 18, 2026, 7:30 PM EDT
Rocket Pharmaceuticals Employees
Rocket Pharmaceuticals had 202 employees as of December 31, 2025. The number of employees decreased by 97 or -32.44% compared to the previous year.
Employees
202
Change (1Y)
-97
Growth (1Y)
-32.44%
Revenue / Employee
n/a
Profits / Employee
-$85,396
Market Cap
369.94M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 202 | -97 | -32.44% |
| Dec 31, 2024 | 299 | 31 | 11.57% |
| Dec 31, 2023 | 268 | 28 | 11.67% |
| Dec 31, 2022 | 240 | 89 | 58.94% |
| Dec 31, 2021 | 151 | 60 | 65.93% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Enanta Pharmaceuticals | 120 |
| Ocugen | 116 |
| BridgeBio Oncology Therapeutics | 88 |
| Orchestra BioMed Holdings | 86 |
| Agenus | 81 |
| X4 Pharmaceuticals | 45 |
| DiaMedica Therapeutics | 35 |
| Fennec Pharmaceuticals | 35 |
RCKT News
- 4 days ago - Needham upgrades Rocket Pharmaceuticals after FDA reaffirms Danon study design - TheFly
- 4 days ago - Rocket Pharmaceuticals upgraded to Buy from Hold at Needham - TheFly
- 5 days ago - Rocket Pharmaceuticals Transcript: Study update - Transcripts
- 5 days ago - Rocket Pharmaceuticals Press release: Study update - Filings
- 5 days ago - Rocket Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 5 days ago - Rocket announces FDA alignment on path to complete Phase 2 trial of RP-A501 - TheFly
- 5 days ago - Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease - Business Wire
- 10 days ago - Rocket Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts